Pyxis Oncology to Participate in September Investor and Industry Conferences
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugate therapeutics, has announced its participation in three upcoming conferences in September 2025.
The company's CEO, Dr. Lara S. Sullivan, will participate in fireside chats at the 2025 Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Additionally, Pyxis will present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit on September 9.
Webcasts for the investor conference presentations will be available on the company's investor relations website.
Pyxis Oncology (Nasdaq: PYXS), azienda in fase clinica dedicata allo sviluppo di terapie a coniugati anticorpo-farmaco, ha annunciato la partecipazione a tre conferenze previste a settembre 2025.
La CEO, Dr. Lara S. Sullivan, prender脿 parte a fireside chat al 2025 Cantor Global Healthcare Conference il 3 settembre e all'H.C. Wainwright Global Investment Conference l'8 settembre. Inoltre, Pyxis terr脿 una presentazione al 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit il 9 settembre.
I webcast delle presentazioni rivolte agli investitori saranno disponibili sul sito web delle relazioni con gli investitori della societ脿.
Pyxis Oncology (Nasdaq: PYXS), una compa帽铆a en fase cl铆nica centrada en el desarrollo de terapias con conjugados anticuerpo-f谩rmaco, ha anunciado su participaci贸n en tres conferencias programadas para septiembre de 2025.
La directora ejecutiva, Dr. Lara S. Sullivan, participar谩 en charlas informales (fireside chats) en la 2025 Cantor Global Healthcare Conference el 3 de septiembre y en la H.C. Wainwright Global Investment Conference el 8 de septiembre. Adem谩s, Pyxis presentar谩 en la 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit el 9 de septiembre.
Las retransmisiones web de las presentaciones para inversores estar谩n disponibles en la web de relaciones con inversores de la compa帽铆a.
Pyxis Oncology (Nasdaq: PYXS), 頃泊-鞎诫 鞝戫暕觳� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 旮办梾鞚� 2025雲� 9鞗� 鞓堨爼霅� 靹� 瓿踌潣 旎嵓霟办姢 彀戈皜毳� 氚滍憸頄堨姷雼堧嫟.
颁贰翱鞚� Dr. Lara S. Sullivan鞚� 9鞗� 3鞚� 2025 Cantor Global Healthcare Conference鞕� 9鞗� 8鞚� H.C. Wainwright Global Investment Conference鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂楈棎 彀胳棳頃╇媹雼�. 霕愴暅 Pyxis電� 9鞗� 9鞚� 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit鞐愳劀 氚滍憸毳� 歆勴枆頃╇媹雼�.
韴瀽鞛� 雽�靸� 氚滍憸鞚� 鞗轨簮鞀ろ姼電� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
Pyxis Oncology (Nasdaq: PYXS), soci茅t茅 en phase clinique d茅di茅e au d茅veloppement de conjugu茅s anticorps-m茅dicament, a annonc茅 sa participation 脿 trois conf茅rences pr茅vues en septembre 2025.
La PDG, Dr. Lara S. Sullivan, prendra part 脿 des 芦 fireside chats 禄 lors du 2025 Cantor Global Healthcare Conference le 3 septembre et du H.C. Wainwright Global Investment Conference le 8 septembre. De plus, Pyxis pr茅sentera lors du 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit le 9 septembre.
Les webcasts des pr茅sentations destin茅es aux investisseurs seront disponibles sur le site relations investisseurs de la soci茅t茅.
Pyxis Oncology (Nasdaq: PYXS), ein Unternehmen in klinischer Phase, das sich auf die Entwicklung von Antik枚rper-Wirkstoff-Konjugaten spezialisiert hat, hat seine Teilnahme an drei Konferenzen im September 2025 angek眉ndigt.
Die CEO, Dr. Lara S. Sullivan, wird am 2025 Cantor Global Healthcare Conference am 3. September und am H.C. Wainwright Global Investment Conference am 8. September an Fireside-Chats teilnehmen. Dar眉ber hinaus wird Pyxis am 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit am 9. September pr盲sentieren.
Webcasts der Investor-Pr盲sentationen werden auf der Investor-Relations-Website des Unternehmens verf眉gbar sein.
- None.
- None.
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences.
Investor Conferences
- 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET 鈥� Fireside chat and investor one-on-one meetings.
- H.C. Wainwright 27th Annual Global Investment Conference, New York, NY, Monday, September 8, 10:30 a.m. ET 鈥� Fireside chat and investor one-on-one meetings.
Industry Conference
- 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit, Boston, MA, Tuesday, September 9, 3:20 p.m. ET 鈥� Company presentation (not webcast).
Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology鈥檚 website, .
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The Company is efficiently building therapeutics that hold the potential for monotherapy and combination indications. Its lead candidate, micvotabart pelidotin (MICVO, formerly PYX-201), has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. Additionally, the Company initiated a Phase 1/2 combination study of MICVO and Merck鈥檚 anti-PD-1 therapy, KEYTRUDA庐 (pembrolizumab), in patients with R/M HNSCC and other advanced solid tumors.
To learn more, visit聽聽or follow us on聽听补苍诲听.
Pyxis Oncology Contact
Jitu Wadhane
Principal Financial and Accounting Officer
Media
Molly Devlin
AG真人官方 Chemistry
FAQ
When is Pyxis Oncology (PYXS) presenting at the Cantor Global Healthcare Conference 2025?
Where can I watch Pyxis Oncology's (PYXS) conference presentations?
What conferences will Pyxis Oncology (PYXS) attend in September 2025?
Who will represent Pyxis Oncology (PYXS) at these conferences?
